Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.62
CYTX's Cash-to-Debt is ranked lower than
90% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CYTX: 0.62 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 2.51 Max: No Debt
Current: 0.62
Equity-to-Asset 0.35
CYTX's Equity-to-Asset is ranked lower than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTX: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.15 Max: 0.94
Current: 0.35
-0.83
0.94
Debt-to-Equity 1.29
CYTX's Debt-to-Equity is ranked lower than
96% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CYTX: 1.29 )
Ranked among companies with meaningful Debt-to-Equity only.
CYTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.16  Med: 0.16 Max: 45.22
Current: 1.29
-8.16
45.22
Piotroski F-Score: 2
Altman Z-Score: -18.43
Beneish M-Score: -3.10
WACC vs ROIC
16.48%
-128.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -241.20
CYTX's Operating Margin % is ranked lower than
60% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CYTX: -241.20 )
Ranked among companies with meaningful Operating Margin % only.
CYTX' s Operating Margin % Range Over the Past 10 Years
Min: -3958.33  Med: -244.92 Max: -131.11
Current: -241.2
-3958.33
-131.11
Net Margin % -273.22
CYTX's Net Margin % is ranked lower than
61% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CYTX: -273.22 )
Ranked among companies with meaningful Net Margin % only.
CYTX' s Net Margin % Range Over the Past 10 Years
Min: -3620.2  Med: -240.66 Max: -157.61
Current: -273.22
-3620.2
-157.61
ROE % -192.80
CYTX's ROE % is ranked lower than
90% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CYTX: -192.80 )
Ranked among companies with meaningful ROE % only.
CYTX' s ROE % Range Over the Past 10 Years
Min: -596.71  Med: -339.9 Max: -190.12
Current: -192.8
-596.71
-190.12
ROA % -67.74
CYTX's ROA % is ranked lower than
75% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CYTX: -67.74 )
Ranked among companies with meaningful ROA % only.
CYTX' s ROA % Range Over the Past 10 Years
Min: -127.5  Med: -64.74 Max: -49.06
Current: -67.74
-127.5
-49.06
ROC (Joel Greenblatt) % -905.82
CYTX's ROC (Joel Greenblatt) % is ranked lower than
62% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CYTX: -905.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1697.26  Med: -1143.13 Max: -620.81
Current: -905.82
-1697.26
-620.81
3-Year Revenue Growth Rate -36.50
CYTX's 3-Year Revenue Growth Rate is ranked lower than
81% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYTX: -36.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.25 Max: 88.4
Current: -36.5
0
88.4
3-Year EBITDA Growth Rate -38.10
CYTX's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CYTX: -38.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.3  Med: -16.3 Max: 37.5
Current: -38.1
-39.3
37.5
3-Year EPS without NRI Growth Rate -38.70
CYTX's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CYTX: -38.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: -14 Max: 102.7
Current: -38.7
-41.5
102.7
GuruFocus has detected 3 Warning Signs with Cytori Therapeutics Inc $CYTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CYTX Guru Trades in Q3 2015

George Soros Sold Out
» More
Q4 2016

CYTX Guru Trades in Q4 2016

Jim Simons 10,091 sh (New)
» More
Q1 2017

CYTX Guru Trades in Q1 2017

Jim Simons 40,091 sh (+297.29%)
» More
Q2 2017

CYTX Guru Trades in Q2 2017

Jim Simons 149,891 sh (+273.88%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 339112    SIC: 3841
Compare:NAS:RPRX, OTCPK:RGIN, TSXV:KALY, NAS:SBOT, OTCPK:MJNE, NAS:SNGX, NAS:RXII, OTCPK:IMUN, OTCPK:MATN, NAS:BSTG, NAS:CLSN, NAS:TENX, AMEX:HEB, NAS:ARGS, OTCPK:ZIVO, NAS:GALE, OTCPK:OBMP, AMEX:APHB, NAS:ANTH, OTCPK:TSOI » details
Traded in other countries:XMPB.Germany,
Headquarter Location:USA
Cytori Therapeutics Inc is a specialty therapeutics company. It develops cellular therapies designed to repair injured tissue, preserve function, improve the quality of life, and modify disease progression.

Cytori Therapeutics Inc is a specialty therapeutics company. It is committed to providing meaningful and quality therapeutic options with a broad utility that benefit patients and healthcare providers around the world. To meet this objective, the company has two therapeutic development platforms, Cytori Cell Therapy (CCT) and Cytori Nanomedicine. The company's CCT, platform, is based on the scientific discovery that the human adipose or fat tissue compartment is a source of a unique mixed population of stem, progenitor and regenerative cells. Its Cytori Nanomedicine Platform features a versatile and novel protein-stabilized liposomal nanoparticle technology for drug encapsulation that provides the foundation to bring two promising drugs into early/late stage clinical trials.

Ratios

vs
industry
vs
history
PB Ratio 1.16
CYTX's PB Ratio is ranked higher than
54% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CYTX: 1.16 )
Ranked among companies with meaningful PB Ratio only.
CYTX' s PB Ratio Range Over the Past 10 Years
Min: 0.95  Med: 27.45 Max: 796.55
Current: 1.16
0.95
796.55
PS Ratio 0.99
CYTX's PS Ratio is ranked higher than
87% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CYTX: 0.99 )
Ranked among companies with meaningful PS Ratio only.
CYTX' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 11.18 Max: 43.15
Current: 0.99
0.82
43.15
EV-to-EBIT -0.89
CYTX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CYTX: -0.89 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16  Med: -4.8 Max: 60.4
Current: -0.89
-16
60.4
EV-to-EBITDA -0.96
CYTX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CYTX: -0.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.5  Med: -5.1 Max: 29.7
Current: -0.96
-17.5
29.7
EV-to-Revenue 2.18
CYTX's EV-to-Revenue is ranked higher than
75% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CYTX: 2.18 )
Ranked among companies with meaningful EV-to-Revenue only.
CYTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 11.5 Max: 44.1
Current: 2.18
1.8
44.1
Current Ratio 1.18
CYTX's Current Ratio is ranked lower than
89% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CYTX: 1.18 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.85 Max: 32.68
Current: 1.18
0.94
32.68
Quick Ratio 0.86
CYTX's Quick Ratio is ranked lower than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CYTX: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 2.57 Max: 31.14
Current: 0.86
0.62
31.14
Days Inventory 502.52
CYTX's Days Inventory is ranked lower than
94% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CYTX: 502.52 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s Days Inventory Range Over the Past 10 Years
Min: 70.92  Med: 307.36 Max: 539.3
Current: 502.52
70.92
539.3
Days Sales Outstanding 33.68
CYTX's Days Sales Outstanding is ranked higher than
77% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CYTX: 33.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.15  Med: 64.69 Max: 124.26
Current: 33.68
4.15
124.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -60.50
CYTX's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CYTX: -60.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.9  Med: -22.85 Max: 2.6
Current: -60.5
-66.9
2.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.09
CYTX's Price-to-Median-PS-Value is ranked higher than
93% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CYTX: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.05 Max: 3.81
Current: 0.09
0.19
3.81
Earnings Yield (Greenblatt) % -112.36
CYTX's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CYTX: -112.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -138.7  Med: -19.95 Max: 2.9
Current: -112.36
-138.7
2.9

More Statistics

Revenue (TTM) (Mil) $8.75
EPS (TTM) $ -1.00
Beta2.93
Short Percentage of Float8.11%
52-Week Range $0.28 - 2.14
Shares Outstanding (Mil)34.72

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 10 25 70 113
EPS ($) -0.72 -0.36 1.01 1.68
EPS without NRI ($) -0.72 -0.36 1.01 1.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Cytori Announces Corporate Restructuring & Cost Reduction Plan Sep 01 2017 
Cytori to Webcast Second Quarter Financial Results on August 10 Aug 04 2017 
Cytori Therapeutics Announces Inducement Grants for New Employees Jul 25 2017 
Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Jul 24 2017 
American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderm Jul 10 2017 
Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin Am Jun 14 2017 
Cytori to Introduce Next-Generation Celution® Technology Jun 01 2017 
Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial May 31 2017 
Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial May 23 2017 
Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor May 16 2017 

More From Other Websites
ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017 Sep 07 2017
Cytori Announces Corporate Restructuring & Cost Reduction Plan Sep 01 2017
ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017 Aug 25 2017
Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment Aug 17 2017
Edited Transcript of CYTX earnings conference call or presentation 10-Aug-17 9:30pm GMT Aug 16 2017
Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Aug 16 2017
Cytori reports 2Q loss Aug 10 2017
Investor Network: Cytori Therapeutics, Inc. to Host Earnings Call Aug 10 2017
Cytori Reports Second Quarter 2017 Business and Financial Results Aug 10 2017
Cytori to Webcast Second Quarter Financial Results on August 10 Aug 04 2017
Cytori Therapeutics Announces Inducement Grants for New Employees Jul 25 2017
Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax Jul 25 2017
Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab... Jul 24 2017
Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in... Jul 24 2017
American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma... Jul 10 2017
Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? Jul 07 2017
Cytori Receives Key Cell Therapy Patent for Scleroderma Jul 06 2017
ETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017 Jul 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}